1. Home
  2. FCBC vs NGNE Comparison

FCBC vs NGNE Comparison

Compare FCBC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Community Bankshares Inc. (VA)

FCBC

First Community Bankshares Inc. (VA)

HOLD

Current Price

$48.36

Market Cap

842.5M

Sector

Finance

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$34.41

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FCBC
NGNE
Founded
1874
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
842.5M
744.9M
IPO Year
1996
2014

Fundamental Metrics

Financial Performance
Metric
FCBC
NGNE
Price
$48.36
$34.41
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$63.57
AVG Volume (30 Days)
77.6K
310.4K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
5.26%
N/A
EPS Growth
N/A
0.93
EPS
0.63
N/A
Revenue
N/A
N/A
Revenue This Year
$12.28
N/A
Revenue Next Year
$2.55
N/A
P/E Ratio
$75.02
N/A
Revenue Growth
N/A
N/A
52 Week Low
$31.21
$15.93
52 Week High
$47.50
$43.66

Technical Indicators

Market Signals
Indicator
FCBC
NGNE
Relative Strength Index (RSI) 71.10 47.61
Support Level $41.51 $18.24
Resistance Level N/A $37.27
Average True Range (ATR) 1.29 3.04
MACD 0.34 -0.65
Stochastic Oscillator 93.90 17.67

Price Performance

Historical Comparison
FCBC
NGNE

About FCBC First Community Bankshares Inc. (VA)

First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: